---
figid: PMC10962462__BTT-18-79-g0002
figtitle: Novel molecular targets in endometrial cancer (EC)
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10962462
filename: BTT-18-79-g0002.jpg
figlink: /pmc/articles/PMC10962462/figure/F2
number: F2
caption: Novel molecular targets in endometrial cancer (EC). Numerous pathways are
  involved in EC and they have become targets of interest in the development of current
  therapies. Different agents have been studied alone or in combination approaches
  to target cross-talk pathways including PI3K/AKT/mTOR, HER2, DNA damage response
  pathway, hormone receptors, cancer microenvironment (ie immune cells, cytokines,
  angiogenic factors, growth factors), and metabolic vulnerabilities and improve drug
  delivery by leveraging cancer cell surface antigens. A deepened understanding of
  the molecular subtypes of EC, genomic diversity and oncogenic drivers will improve
  translational research and derive in recognition of mechanisms of resistance and
  molecularly driven therapy.16 Created with Biorender.com
papertitle: 'Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives
  for Therapy'
reftext: Pamela Soberanis Pina, et al. Biologics. 2024;18(NA).
year: '2024'
doi: 10.2147/BTT.S369783
journal_title: 'Biologics : Targets & Therapy'
journal_nlm_ta: Biologics
publisher_name: Dove
keywords: endometrial cancer | targeted therapy | molecular targets | precision medicine
automl_pathway: 0.8286865
figid_alias: PMC10962462__F2
figtype: Figure
redirect_from: /figures/PMC10962462__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10962462__BTT-18-79-g0002.html
  '@type': Dataset
  description: Novel molecular targets in endometrial cancer (EC). Numerous pathways
    are involved in EC and they have become targets of interest in the development
    of current therapies. Different agents have been studied alone or in combination
    approaches to target cross-talk pathways including PI3K/AKT/mTOR, HER2, DNA damage
    response pathway, hormone receptors, cancer microenvironment (ie immune cells,
    cytokines, angiogenic factors, growth factors), and metabolic vulnerabilities
    and improve drug delivery by leveraging cancer cell surface antigens. A deepened
    understanding of the molecular subtypes of EC, genomic diversity and oncogenic
    drivers will improve translational research and derive in recognition of mechanisms
    of resistance and molecularly driven therapy.16 Created with Biorender.com
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - AZIN2
  - GADL1
  - TF
  - FOLR1
  - TACSTD2
  - VTCN1
  - EGFR
  - ERBB2
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - IARS1
  - IRS1
  - IRS2
  - IRS4
  - CD274
  - PDCD1LG2
  - MST1
  - STK4
  - STK3
  - SAV1
  - KRAS
  - HRAS
  - NRAS
  - CUX1
  - SART3
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - ESR1
  - ERAL1
  - IFNA1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - YAP1
  - TAFAZZIN
  - WWTR1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - TSC1
  - CCL26
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - STK11
  - MTOR
  - CGAS
  - STING1
  - XPO1
  - RPTOR
  - MAPKAP1
  - RICTOR
  - MLST8
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - ATP8A2
  - ATM
  - ATR
  - ANTXR1
  - MMAB
  - SERPINA2
  - MTG1
  - CHEK2
  - CHEK1
  - TP53
  - TP63
  - TP73
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - CDC25C
  - RASGRF1
  - CDC25A
  - CDC25B
  - CCNH
  - CDK7
  - CCNB1
  - CCNB2
  - CCNB3
  - CCNE1
  - CCNE2
  - CDK1
  - CDKL1
  - CDKL2
  - CDKL3
  - CDKL4
  - CDKL5
  - CDK3
  - CDK4
  - CDK5
  - CDK6
  - CDK8
  - CDK9
  - CDK10
  - CDK11A
  - CDK11B
  - CDK12
  - CDK13
  - CDK14
  - CDK15
  - CDK16
  - CDK17
  - CDK18
  - CDK19
  - CDK20
  - CDK2
  - WEE1
  - MYT1
  - PKMYT1
  - CCND1
  - CCND2
  - CCND3
  - WARS1
  - E2F1
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - E2F8
  - CCNA1
  - CCNA2
  - inhibitors
  - Lenvatinib
  - Sunitinib
  - Neoantigens
  - Insulin
  - Erlotinib
  - ADC
  - Tamoxifen
  - RAS
  - ERA
  - Selumetinib
  - Trametinib
  - AZD5363
  - Fulvestrant
  - Everolimus
  - Metformin
  - Selinexor
  - ERa
  - PARP
  - Olaparib
  - DNA
  - ATP
  - Camonsertib
  - GTP
  - Adavosertib
  - Palbociclib
  - cancer
  - endometrial cancer
---
